Abstract: Objective This clinical trial was conducted to investigate efficacy and safety of sofebuvir and redipavir combination in the treatment of patients with chronic hepatitis C (CHC). Methods Forty-eight patients with CHC were enrolled in our hospital between February 2017 and March 2023, and were randomly divided into observation (n=24) and control group (n=24), receiving sofebuvir and redipavir combination for 12 weeks or peginterferon-α and ribavirin combination for 24 weeks, respectively. Rapid virological response (RVR), end of treatment (EOT) virological response (ETVR) and sustained virological response (SVR) were recorded. Results The clinical materials including HCV genotypes at baseline in the two groups were comparable (P>0.05); RVR, ETVR and SVR in the DAA-treated patients were 75.0%, 95.8% and 95.8%, all much higher than 58.3%, 70.8% and 66.7% (P<0.05) in peginterferon-α-treated patients; by end of antiviral treatment, platelet and white blood cell counts in DAA-treated patients were (201.5±22.3)×10⁹/L and (6.5±1.4)×10⁹/L, both significantly higher than [(137.6±15.0)×10⁹/L and (3.7±1.3)×10⁹/L, P<0.05], while serum ALT level was (36.2±4.3)U/L, much lower than [(60.8±5.4)U/L, P<0.05] in peginterferon-α-treated patients; during antiviral treatment, adverse events rates, such as fever occurred in 83.3%, granulocytopenia in 62.5% and thrombocytopenia in 41.7% in peginterferon-α-treated patients. Conclusion Sofebuvir and redipavir combination therapy in treatment of patients with CHC has a satisfactory efficacy and relatively less adverse events, which warrants widespread clinical application.

Key words: Hepatitis C, Sofeibuvir, Radipavir, Therapy